publication date: Feb. 6, 2015

Candace Johnson Named CEO of Roswell Park Cancer Institute

 

CANDACE JOHNSON was named the 15th president and CEO of Roswell Park Cancer Institute. Johnson will be the first female leader for the 117-year-old comprehensive cancer center.

She served as deputy director of Roswell Park, as well as chair of the Department of Pharmacology and Therapeutics, the Wallace Family Chair for Translational Research and professor of oncology. During that time, she has helped secure the NCI’s coveted Cancer Center Support Grant twice.

Since November 2014, she has also served as cancer center director, and served as interim president and CEO of the institute since last October.

Before coming to Roswell Park, she served as deputy director of basic research at the University of Pittsburgh Cancer Institute, and professor of pharmacology and medicine at the University of Pittsburgh School of Medicine.

 

THOMAS RUTHERFORD was named network physician director of cancer services for the Western Connecticut Health Network.

Rutherford will help create a new model of cancer delivery, building on the existing programs at the Praxair Cancer Center at Danbury Hospital, the Diebold Family Cancer Center at New Milford Hospital and the Whittingham Cancer Center at Norwalk Hospital.

Prior to WCHN, he practiced at Yale Gynecologic Oncology. He served as professor of gynecologic oncology and director of Gynecologic Oncology Fellowship at Yale University School of Medicine, a position he held for 12 years.

Rutherford has focused on prevention, early detection, and treatment of ovarian cancer and other gynecologic malignancies.

 

CAROLYN COMPTON will lead the … Continue reading 41-05 Candace Johnson Named CEO of Roswell Park Cancer Institute

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.